Ⅲ期可手术乳腺癌新辅助化疗的临床疗效

Evaluation on the clinical effect of neo-adjuvant chemotherapy on breast cancer at stage III

目的探讨Ⅲ期可手术乳腺癌新辅助化疗的临床疗效。方法将56例Ⅲ期可手术乳腺癌随机分为新辅助化疗组和对照组。新辅助化疗组术前作3周期CTF(CTX+THP+FUDR)化疗,术后补充放疗、化疗;对照组除不做术前化疗外,手术及术后其他治疗相同。结果新辅助化疗组临床有效率达65%,且其病理组织学改变较对照组明显。两组5年生存率分别为65.8%和54.7%,新辅助化疗组明显高于对照组(P<0.05)。结论新辅助化疗可提高Ⅲ期可手术乳腺癌的临床疗效。

Objective To evaluate the clinical efficacy of the neo - adjuvant chemotherapy （NACT） for operable stage Ⅲ breast cancer. Methods 56 patients with operable stage Ⅲ breast cancer were randomly divided into two groups the neoadiuvant chenro therapy （NACT） group and the control group. The NACT group received a chemotherapy with the regiman of CTF（ CTX ＋ THP ＋ FUDR）for three cycles before operation. The two groups received the same operation and postoperative adjuvant radio - chemotherapy. Results The clinical response rate in NACT group was 65 %. The histological changes in the NACT group was much obvious than those in the control group. The 5 - year survival rates （5YSR） were 65.8% and 54.7% ,respectively showing a significant difference between the two groups （ P 〈 0.05）. Conclusion It is suggested that NACT is clinically effective for operable stage Ⅲ breast cancer.